Literature DB >> 20586542

Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation.

Eva Jöst1, Wynand P Roos, Bernd Kaina, Heinz Schmidberger.   

Abstract

PURPOSE: Clinical trials on pancreatic cancer demonstrated that interferons (IFN) improve the therapeutic index of combined radio- and chemotherapy. This is believed to be due to radiosensitisation of cells, which, however, needs experimental verification.
MATERIALS AND METHODS: Here, we compared the survival response of ten pancreatic tumour cell lines following ionising radiation (IR), interferon-alpha (IFN-alpha), interferon-beta (IFN-beta) and combined treatment. The effect of combination treatment on apoptosis induction was also determined.
RESULTS: In most cell lines IFN treatment on its own exerted cytotoxicity, which was independent of the expression level of the IFN receptor on the cell surface. Three cell lines showed a radiosensitisation effect while two showed radioprotection. Although IFN-alpha is commonly used in the clinic, IFN-beta induced a stronger cytotoxic response than IFN-alpha in vitro. The likely mechanism of enhancement of radiosensitivity in the responsive cell lines was shown to be an increase of the radiation-induced apoptotic response by IFN pretreatment.
CONCLUSIONS: Given that the in vitro data do not conform to the impressive clinical results observed after combined radio- and chemotherapy with IFN-alpha, it is reasonable to conclude that the sensitising effect of IFN is not mediated through modulating the intrinsic radiosensitivity of pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586542     DOI: 10.3109/09553002.2010.481321

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  6 in total

1.  Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.

Authors:  P R A Buijs; C H J van Eijck; L J Hofland; R A M Fouchier; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

2.  Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells.

Authors:  Hong Xu; Jian Xian; Emmanuelle Vire; Steven McKinney; Vivien Wei; Jason Wong; Rebecca Tong; Tony Kouzarides; Carlos Caldas; Samuel Aparicio
Journal:  J Pathol       Date:  2014-08-28       Impact factor: 7.996

3.  Pancreatic cancer: chemotherapy and radiotherapy.

Authors:  Ake Andrén-Sandberg
Journal:  N Am J Med Sci       Date:  2011-01

4.  Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.

Authors:  Daniela Hanisch; Andrea Krumm; Tamara Diehl; Carla M Stork; Mario Dejung; Falk Butter; Ella Kim; Walburgis Brenner; Gerhard Fritz; Thomas G Hofmann; Wynand P Roos
Journal:  Cell Death Dis       Date:  2022-04-01       Impact factor: 8.469

5.  Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells.

Authors:  Stephanie Booy; Casper H J van Eijck; Fadime Dogan; Peter M van Koetsveld; Leo J Hofland
Journal:  J Cell Mol Med       Date:  2014-01-25       Impact factor: 5.310

6.  Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.

Authors:  Amber Blaauboer; Stephanie Booy; Peter M van Koetsveld; Bas Karels; Fadime Dogan; Suzanne van Zwienen; Casper H J van Eijck; Leo J Hofland
Journal:  BMC Cancer       Date:  2020-09-23       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.